Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Outbreak ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Josep Roca-GrandeMicrobiology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-7177-1684
Alba Mir-CrosMicrobiology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0003-4827-9824
Carmen Muñoz-AlmagroInfectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Esplugues, Spain.ORCID 0000-0001-5586-404X
Alba Bellés-BellésDepartment of Clinical Microbiology, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRB-Lleida), Lleida, Spain.ORCID 0000-0001-6277-1239
Jordi CàmaraDepartment of Clinical Microbiology, Hospital Universitari de Bellvitge, IDIBELL-UB, L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-0817-0931
Emilia CercenadoCIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-5279-3773
M Ángeles Galán-LaderoDepartment of Clinical Microbiology, Hospital Universitario Reina Sofía, Córdoba, Spain.
Andrea Martín-NaldaPediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Hospital Universitari Vall d'Hebron Campus, Barcelona, Spain.ORCID 0000-0002-1715-153X
Albert Moreno-MingoranceMicrobiology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-3073-5046
Daniel Navarro de la CruzDepartment of Clinical Microbiology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.ORCID 0000-0002-7556-5861
M Ángeles OrellanaDepartment of Clinical Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Begoña PalopDepartment of Clinical Microbiology, Hospital Regional Universitario de Málaga, Málaga, Spain.
Amaresh Pérez-ArgüelloInfectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Esplugues, Spain.
Guillem Puigsech-BoixedaMicrobiology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0009-0001-6036-5429
M Dolores QuesadaDepartment of Clinical Microbiology, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Spain.ORCID 0000-0001-8360-3787
Alba RiveraDepartment of Genetics and Microbiology, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID 0000-0002-9709-6162
Ana Rodriguez-FernandezDepartment of Clinical Microbiology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.
Enrique Ruiz de GopeguiDepartment of Clinical Microbiology, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.ORCID 0000-0002-8752-6894
Carolina SarviséDepartment of Clinical Microbiology, Hospital Universitari de Tarragona Joan XXIII, Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.
Aleix Soler-GarciaInfectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Esplugues, Spain.ORCID 0000-0001-7190-0653
Nieves LarrosaMicrobiology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0001-8808-0233
Juan José González-LópezMicrobiology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0003-2419-5909
GE-EMIE Study Team
Funding
Wellcome Trust
6 · The paper itself
Abstract
Invasive meningococcal disease (IMD) is associated with significant global morbidity and mortality and is addressed by conjugated polysaccharide and subcapsular vaccines. In Spain, data on 4CMenB vaccine strain coverage and antimicrobial susceptibility are limited. This study aimed to describe the genomic epidemiology, predict 4CMenB vaccine strain coverage, and assess antimicrobial susceptibility of 323
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Genomic characterization of invasive · full record | OpenQuestion